bpm31510 + 5-fluorouracil

**bpm31510 + 5-fluorouracil** is an investigational combination therapy comprised of BPM31510 (a lipid-drug conjugate nanodispersion formulated to deliver supraphysiological concentrations of ubidecarenone [oxidized CoQ10/coenzyme Q10] to mitochondria in cancer cells[1][2][3]) and 5-fluorouracil, a well-established antimetabolite chemotherapeutic. BPM31510 acts by reprogramming tumor metabolism, selectively increasing oxidative stress and mitochondrial reactive oxygen species within cancer cells to induce apoptosis, sparing non-tumor cells due to a differential susceptibility[1][2][3]. 5-fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis and repair, and is commonly used in various solid tumors.

Other names

ubidecarenone + 5-fluorouracilcoenzyme Q10 nanodispersion + 5-fluorouracil